Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,765 across all filing types
Latest filing 2021-02-08 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
We would like to inform that the Board has at its meeting held today approved, inter-alia, the following: 1) Audited Standalone Financial Results along with audit report thereon ....
Interim / Quarterly Report Classification · 95% confidence The document contains an auditor's report on quarterly standalone financial results and standalone year-to-date results for the quarter and nine months ended 31 December 2020. It references Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to quarterly financial results. The document includes detailed audit opinions, management responsibilities, and financial data tables. It also mentions the approval of audited standalone financial results and unaudited consolidated financial results by the Board. The presence of detailed financial statements and audit opinions for a period shorter than a full fiscal year (quarter and nine months) indicates this is an Interim / Quarterly Report. The document is about 15,000 characters long, which is substantial and contains actual financial data, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR).
2021-02-08 English
Financial Result Updates
Regulatory Filings
2021-02-08 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is an official communication from Torrent Pharmaceuticals Limited to stock exchanges (BSE and NSE) regarding the loss of share certificates by certain shareholders. It references Regulation 39 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to the handling of lost or misplaced share certificates. The content includes details of the lost certificates and a request to trading members to refrain from dealing in these shares until duplicates are issued. There is also an enclosed letter from the Registrar and Transfer Agent (RTA) confirming receipt of the information. This document is a regulatory announcement informing the market and stakeholders about the loss of share certificates and the process for issuing duplicates. It does not contain financial data, management discussion, voting results, or other report types. It is not a report publication announcement since it is not about publishing a report but about a regulatory compliance disclosure. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-01-22 English
Intimation of Loss of Share Certificates
Regulatory Filings Classification · 100% confidence The document is an official communication dated January 21, 2021, from Torrent Pharmaceuticals Limited to stock exchanges (BSE and NSE) regarding the loss of share certificates by certain shareholders. It references Regulation 39 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs the reporting of such events. The content includes details of lost share certificates and a request to trading members to refrain from trading these shares. Additionally, it encloses a letter from the Registrar and Transfer Agent (RTA) confirming receipt of the information. The document is a regulatory announcement informing the market and stakeholders about the loss of share certificates and the issuance of duplicates. It does not contain financial data, management discussion, voting results, or other report types. It is not a report publication announcement since it is not about publishing a report but about a regulatory disclosure. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2021-01-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a short announcement informing about a scheduled teleconference (conference call) with investors and analysts to discuss the financial performance for the quarter and nine months ended December 31, 2020. It provides dial-in details for the call but does not contain any financial data or results itself. The document length is only 1832 characters, which is quite short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as a Call Transcript announcement (CT) or more precisely a notice of a conference call. Since it is announcing the call rather than providing the transcript, it fits best under Call Transcript (CT) category as per the definitions, which includes full text transcripts or announcements related to conference calls. Confidence is high given the clear mention of a scheduled conference call and financial period reference.
2021-01-20 English
We hereby inform that the Company has scheduled a teleconference with Investors / Analyst on 8th February, 2021 at 05:30 P.M. to discuss the financial performance of the Company for the ....
Call Transcript Classification · 95% confidence The document is a notification about a scheduled teleconference (conference call) with investors and analysts to discuss the financial performance for the quarter and nine months ended 31st December 2020. It provides dial-in details for the call but does not contain any financial data or results itself. The document length is short (3003 characters) and it is clearly an announcement of a conference call rather than the transcript or report of the call. Therefore, the appropriate classification is Call Transcript (CT) category, as it relates to a conference call event. However, since this is only a notice of the call and not the transcript itself, the best fit is still CT because the document is specifically about the conference call event. Confidence is high due to clear keywords like "conference call", "investors/analyst", and the scheduled date/time for the call.
2021-01-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.